Trials / Conditions / Ann Arbor Stage II Marginal Zone Lymphoma
Ann Arbor Stage II Marginal Zone Lymphoma
3 registered clinical trials studyying Ann Arbor Stage II Marginal Zone Lymphoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma NCT06442475 | University of Washington | Phase 2 |
| Active Not Recruiting | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Ly NCT04323956 | Mayo Clinic | Phase 1 |
| Completed | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage NCT02532257 | M.D. Anderson Cancer Center | Phase 2 |